within Pharmacolibrary.Drugs.ATC.J;

model J01FA08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 0.3333333333333333,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Troleandomycin is a macrolide antibiotic, structurally related to erythromycin. It was formerly used for the treatment of infections caused by susceptible bacteria and also investigated for use in asthma and for steroid-sparing effects. Troleandomycin is currently not widely used in clinical practice and is not approved in many countries.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a typical adult, as there is no published pharmacokinetic study available with detailed compartmental analysis.</p><h4>References</h4><ol><li>J S Wang, W Wang, H G Xie, S L Huang, H H Zhou,Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A.,British journal of clinical pharmacology,1997<a href='https://pubmed.ncbi.nlm.nih.gov/9278210/'>https://pubmed.ncbi.nlm.nih.gov/9278210/</a></li><li>K A Rodvold,Clinical pharmacokinetics of clarithromycin.,Clinical pharmacokinetics,1999<a href='https://pubmed.ncbi.nlm.nih.gov/10589373/'>https://pubmed.ncbi.nlm.nih.gov/10589373/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01FA08;
